passlisted in Coinbase and Binance#2 by calls of 16 on this host
0.2 USDC
per call, as the listing declares it on eip155:
- Validation state
- pass
- Uptime, 7 / 30 / 90 days
- 100% / 100% / 100%
- Calls, trailing 30 days
- 2
- Unique payers, trailing 30 days
- 1
- Last called
- 2026-08-20 14:01 UTC
- First observed by TOLLderived
- 2026-09-10
- Pricederived
- 0.2 USDC
- Networks
- 11
How big is this endpoint among the ones like it?
No trace is drawn of this endpoint’s own volume. Its counters have changed 1 time across 28 observations, and 3 changes are the fewest this site will draw a trace through, because two points and a guess are not a series. Every observation is in the JSON.
clinicalintelpulse.theaslangroupllc.com lists 16 endpoints; clinical sponsor intel is tied 2nd by calls with 9 others.
Its declared inputs are the query parameters lang, focus and sponsor.
clinical sponsor intel returns json; the example shows fda_approvals, phase3_assets, query_summary, pipeline_summary, investment_signals, competitive_position and 1 other.
clinical sponsor intel drew 2 calls from one payer in the trailing 30 days.
The last call to clinical sponsor intel came 26 days before the snapshot, 2026-08-20.
Each call is priced at 0.2 USDC, payable on Base.
clinical sponsor intel takes 7% of the calls counted across clinicalintelpulse.theaslangroupllc.com.
For clinical sponsor intel the listing declares 14 accepts on Base, Solana, Polygon, Arbitrum and 7 others, to 4 different wallets.
TOLL files clinical sponsor intel under inference: a GET endpoint on clinicalintelpulse.theaslangroupllc.com, listed in both the Coinbase and Binance registries.
clinical sponsor intel answered the sweep of 2026-09-15 with a valid 402, as at every sweep since 2026-09-11.
Closest in price to clinical sponsor intel within inference: generate at imagegen.coinopai.com and fal generate at vaaya.ai.
clinical sponsor intel is near the top of prices in inference; 93% of comparable listings are cheaper.
For 9 of the options on clinical sponsor intel, TOLL has no verified decimals and shows the raw amount. clinical sponsor intel declares exact and eip3009 as payment schemes.
Its payee wallet receives for 964 listed endpoints across 78 hosts.
The seller's tags on clinical sponsor intel are pharma-pipeline, sponsor-intel, competitive-intelligence and biotech.
Exactly this price appears on 39 other listings in inference.
the payment options, as of 2026-09-15 16:57 UTC · method · pinnable
| registry | network | asset | amount | scheme | pay to |
|---|---|---|---|---|---|
| Coinbase | eip155: | USDC | 0.2 USDC | exact | 0x50ab20…4912fc |
| Coinbase | eip155: | USDC | 0.2 USDC | exact | 0x50ab20…4912fc |
| Coinbase | solana: | USDC | 0.2 USDC | exact | 985iFjbn…4B5KX1 |
| Coinbase | eip155: | USDC | 0.2 USDC | exact | 0x50ab20…4912fc |
| Coinbase | eip155: | USDC | 0.2 USDC | exact | 0x50ab20…4912fc |
| Coinbase | eip155: | USDC | 200000 smallest units, decimals unknown | exact | 0x50ab20…4912fc |
| Coinbase | eip155: | USDC | 200000 smallest units, decimals unknown | exact | 0x50ab20…4912fc |
| Coinbase | eip155: | USD₮0 | 200000 smallest units, decimals unknown | exact | 0x50ab20…4912fc |
| Coinbase | eip155: | USDC | 200000 smallest units, decimals unknown | exact | 0x50ab20…4912fc |
| Coinbase | algorand: | 31566704 | 200000 smallest units, decimals unknown | exact | 62A253YP…FWGI7I |
| Coinbase | xrpl: | XRP | 200000 smallest units, decimals unknown | exact | rMnHeutY…pPEh32 |
| Coinbase | xrpl: | 524C5553…000000 | amount not declared | exact | rMnHeutY…pPEh32 |
| Coinbase | eip155: | World Liberty Financial USD | 200000000000000000 smallest units, decimals unknown | exact | 0x50ab20…4912fc |
| Binance | eip155: | 0x8d0d00…f08b0d | 200000000000000000 smallest units, decimals unknown | eip3009 | 0x50ab20…4912fc |
the checks, as of 2026-09-15 05:38 UTC · method · pinnableendpoint answered HTTP 402
No named check failed.
Every sweep that observed this endpoint, newest first.
| observed, UTC | state | failed checks | sweep |
|---|---|---|---|
| 2026-09-15 05:38 UTC | pass | 0 | daily-2026-09-15 |
| 2026-09-14 05:12 UTC | pass | 0 | daily-2026-09-14 |
| 2026-09-13 05:08 UTC | pass | 0 | daily-2026-09-13 |
| 2026-09-12 07:24 UTC | pass | 0 | daily-2026-09-12 |
| 2026-09-11 11:07 UTC | pass | 0 | daily-2026-09-11 |
Presence in a registry, not liveness of the service (method). Newest first.
- listed in Coinbase
- listed in Binance
From the registry record, not validated by TOLL.the declared schema, as of 2026-08-20 14:01 UTC · method · live
The input and output block
{
"input": {
"type": "http",
"method": "GET",
"queryParams": {
"lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
"focus": "pipeline | approvals | deals | all (default: all)",
"sponsor": "Company name — e.g. \"Moderna\" | \"BioNTech\" | \"Alnylam\" | \"Vertex Pharmaceuticals\" | \"Regeneron\""
}
},
"output": {
"type": "json",
"example": {
"fda_approvals": [
{
"drug": "Patisiran (Onpattro)",
"type": "NDA",
"approved": "2018",
"indication": "hATTR polyneuropathy",
"first_in_class": true
},
{
"drug": "Givosiran (Givlaari)",
"type": "NDA",
"approved": "2019",
"indication": "Acute hepatic porphyria"
}
],
"phase3_assets": [
{
"drug": "Vutrisiran (Amvuttra)",
"nctId": "NCT04153149",
"status": "ACTIVE_NOT_RECRUITING",
"condition": "ATTR Cardiomyopathy",
"completion": "2025-Q3",
"significance": "Key label expansion into ATTR-CM — $3B+ market"
}
],
"query_summary": {
"focus": "all",
"sponsor": "Alnylam Pharmaceuticals"
},
"pipeline_summary": {
"phase1_count": 8,
"phase2_count": 9,
"phase3_count": 6,
"total_active_trials": 23,
"primary_therapeutic_areas": [
"Rare genetic diseases (TTR, PH1, AHP)",
"Cardiovascular (inclisiran)",
"CNS (Huntington's)"
]
},
"investment_signals": {
"risks": [
"Pricing pressure in rare disease",
"RNAi delivery competition from Arrowhead"
],
"near_term_catalysts": [
"HELIOS-B ATTR-CM readout 2025",
"ALN-APP Phase 2 for early Alzheimer's"
],
"pipeline_value_estimate": "$12-18B risk-adjusted NPV"
},
"competitive_position": "Global leader in RNAi therapeutics. 6 approved drugs. Patent portfolio dominant through 2035+.",
"partnership_activity": "Novartis partnership (inclisiran, cardiovascular) — $9.7B deal. Roche collaborations ongoing. Regeneron RNAi collaboration $400M+."
}
}
}Cite this page
The pinned URL below renders this page from the snapshot of 2026-09-15 16:57 UTC and does not change; the live page does, every six hours. Data reuse is under CC BY 4.0 (terms).
Plain text
TOLL, "clinical sponsor intel on clinicalintelpulse.theaslangroupllc.com", snapshot of 2026-09-15 16:57 UTC. https://tollindex.com/e/clinicalintelpulse-theaslangroupllc-com-api-clinical-sponsor-intel-7efa9c/at/2026-09-15T16-57Z. Accessed [access date].
BibTeX
@misc{toll-e-clinicalintelpulse-theaslangroupllc-com-api-clinical-sponsor-intel-7efa9c-2026-09-15T16-57Z,
author = {TOLL},
title = {clinical sponsor intel on clinicalintelpulse.theaslangroupllc.com},
howpublished = {\url{https://tollindex.com/e/clinicalintelpulse-theaslangroupllc-com-api-clinical-sponsor-intel-7efa9c/at/2026-09-15T16-57Z}},
year = {2026},
month = {9},
note = {Pinned view of the snapshot of 2026-09-15 16:57 UTC. Accessed [access date].}
}None yet. Anything submitted through the form below is published here with its outcome.